Zobrazeno 1 - 10
of 50
pro vyhledávání: '"C H Dash"'
Autor:
C. H. Dash, S. J. Leach, R. J. Levy, James N. Moy, Mark Ballow, R. L. Roberts, A. M. Scharenberg, Mary Beth Fasano, Mark R. Stein, D. Suez
Publikováno v:
Clinical and Experimental Immunology. 162:510-515
Summary This open-label multi-centre study evaluated a new intravenous immunoglobulin, Gammaplex®, in the treatment of 50 patients with primary immunodeficiency and significant hypogammglobulinaemia. Patients treated previously with other intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f5cee63edb778a68503bf39c33dcbe
https://doi.org/10.1111/j.1365-2249.2010.04247.x
https://doi.org/10.1111/j.1365-2249.2010.04247.x
Publikováno v:
Pharmacoepidemiology and Drug Safety. 13:243-252
To assess the safety of a highly purified, plasma-derived factor VIII concentrate (Replenate) in routine clinical use.Following guidelines entitled safety assessment of marketed medicines (SAMM), safety data were collected in the UK on 194 patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35d870d0d2887514255b4b82a9eb0e8f
https://doi.org/10.1002/pds.956
https://doi.org/10.1002/pds.956
Publikováno v:
Pharmacoepidemiology and Drug Safety. 13:187-195
Purpose To assess the safety of a highly purified, plasma-derived factor VIII concentrate (Replenate®) in routine clinical use. Methods Following guidelines entitled safety assessment of marketed medicines (SAMM), safety data were collected in the U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99874df5ce1e4fa2adfa8270daee655b
https://doi.org/10.1002/pds.911
https://doi.org/10.1002/pds.911
Autor:
M, Matysiak, H, Bobrowska, W, Balwierz, A, Chybicka, J R, Kowalczyk, R, Shaikh-Zaidi, K, Gillanders, C H, Dash
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17(5)
Optivate® is a high-purity FVIII/VWF product. Its safety, tolerability and efficacy in subjects ≥ 12 years have been demonstrated. This study was undertaken to assess Optivate® in children with haemophilia A. Twenty-five children, including one P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f20e31abcb68a6bf6ae947605bdef6e
https://pubmed.ncbi.nlm.nih.gov/21699629
https://pubmed.ncbi.nlm.nih.gov/21699629
Autor:
C R M, Hay, A, Hellmann, A, Dmoszynska, T, Baglin, D, O'Shaunessey, M, Makris, R, Shaikh-Zaidi, C H, Dash
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 17(3)
The efficacy and safety of Optivate(®) was assessed in 23 surgical operations, orthopaedic (12) including 5 revision arthroplasties, ophthalmic (1), ENT (1), dental (6), liver biopsy (2), and removal of portacath (1) on 15 teenagers and adults with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b368e0ff89b45ddf06398d874a686a50
https://pubmed.ncbi.nlm.nih.gov/21371182
https://pubmed.ncbi.nlm.nih.gov/21371182
Autor:
J. R. Ballinger, A. M. Peters, C. H. Dash, M. J. Norton, G. E. Chapman, C. Cousins, D. R. Parry-Jones, N. A. Beharry
Summary Anti-D is given routinely to pregnant RhD-negative women to prevent haemolytic disease of the fetus and newborn. To overcome the potential drawbacks associated with plasma-derived products, monoclonal and recombinant forms of anti-D have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e843af5262da1545613c757eec7ee1ae
https://europepmc.org/articles/PMC2219283/
https://europepmc.org/articles/PMC2219283/
Publikováno v:
Pharmacoepidemiology and drug safety. 13(3)
To assess the safety of a plasma-derived highly purified factor IX concentrate (Replenine) in routine clinical use.Following guidelines entitled Safety Assessment of Marketed Medicines (SAMM), safety data were collected in the UK by retrospective rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a51280e7240101865c3ebd5a594346e1
https://pubmed.ncbi.nlm.nih.gov/15072119
https://pubmed.ncbi.nlm.nih.gov/15072119
Publikováno v:
Vox sanguinis. 80(3)
The tolerability and pharmacokinetics of a solvent/detergent-treated intramuscular immunoglobulin were compared with those of the standard product.Single, 750-mg intramuscular (i.m.) injections were administered to a total of 36 healthy individuals:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fdf8aef943754215e0cc157fcc15b38c
https://pubmed.ncbi.nlm.nih.gov/11449954
https://pubmed.ncbi.nlm.nih.gov/11449954
Publikováno v:
Vox sanguinis. 77(4)
To see if modifications to the processing of intravenous immunoglobulin to include a virus inactivation stage alter immunoglobulin G (IgG) resulting in hypotension in patients.Clinical trials were done involving extensive patient monitoring during in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::73d7c9f3d7a55617eb356d40e82cf7a4
https://pubmed.ncbi.nlm.nih.gov/10717599
https://pubmed.ncbi.nlm.nih.gov/10717599
Autor:
C H Dash
Publikováno v:
BMJ. 316:1017-1017
EDITOR—Warden's news item about blood products made from plasma from donors in the United Kingdom is inaccurate in its main message.1 Products manufactured from plasma from donors in the United Kingdom have not been banned. Both BPL (Bio Products L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f114d91f36bc3f4da6cdc07af6d2502
https://doi.org/10.1136/bmj.316.7136.1017a
https://doi.org/10.1136/bmj.316.7136.1017a